Amount of eligible people: CDEC discussed the uncertainty in the amount of people with reasonably extreme to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals that are categorised as obtaining gentle or average disease can have a extreme bleeding phenotype, https://hemgenix71593.blogitright.com/36059866/hemgenix-an-overview